Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,710 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated Pathways.
Rios-Doria J, Sabol D, Chesebrough J, Stewart D, Xu L, Tammali R, Cheng L, Du Q, Schifferli K, Rothstein R, Leow CC, Heidbrink-Thompson J, Jin X, Gao C, Friedman J, Wilkinson B, Damschroder M, Pierce AJ, Hollingsworth RE, Tice DA, Michelotti EF. Rios-Doria J, et al. Among authors: stewart d. Mol Cancer Ther. 2015 Jul;14(7):1637-49. doi: 10.1158/1535-7163.MCT-14-1040. Epub 2015 May 6. Mol Cancer Ther. 2015. PMID: 25948294
Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies.
Rios-Doria J, Harper J, Rothstein R, Wetzel L, Chesebrough J, Marrero A, Chen C, Strout P, Mulgrew K, McGlinchey K, Fleming R, Bezabeh B, Meekin J, Stewart D, Kennedy M, Martin P, Buchanan A, Dimasi N, Michelotti E, Hollingsworth R. Rios-Doria J, et al. Among authors: stewart d. Cancer Res. 2017 May 15;77(10):2686-2698. doi: 10.1158/0008-5472.CAN-16-2854. Epub 2017 Mar 10. Cancer Res. 2017. PMID: 28283653
An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
Jakubczak JL, Ryan P, Gorziglia M, Clarke L, Hawkins LK, Hay C, Huang Y, Kaloss M, Marinov A, Phipps S, Pinkstaff A, Shirley P, Skripchenko Y, Stewart D, Forry-Schaudies S, Hallenbeck PL. Jakubczak JL, et al. Among authors: stewart d. Cancer Res. 2003 Apr 1;63(7):1490-9. Cancer Res. 2003. PMID: 12670895
Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer.
Ryan PC, Jakubczak JL, Stewart DA, Hawkins LK, Cheng C, Clarke LM, Ganesh S, Hay C, Huang Y, Kaloss M, Marinov A, Phipps SS, Reddy PS, Shirley PS, Skripchenko Y, Xu L, Yang J, Forry-Schaudies S, Hallenbeck PL. Ryan PC, et al. Cancer Gene Ther. 2004 Aug;11(8):555-69. doi: 10.1038/sj.cgt.7700735. Cancer Gene Ther. 2004. PMID: 15232601
Genomic ascertainment to quantify prevalence and cancer risk in adults with pathogenic and likely pathogenic germline variants in RASopathy genes.
Kim J, Ney G, Frone MN, Haley JS, Mirshahi UL, Astiazaran-Symonds E, Shandrina M, Urban G, Rao HS, Stahl R, Golden A, Yohe ME, Gross AM, Ding Y, Carey DJ, Gelb BD, Stewart DR. Kim J, et al. Among authors: stewart dr. medRxiv [Preprint]. 2024 Oct 11:2024.10.09.24314324. doi: 10.1101/2024.10.09.24314324. medRxiv. 2024. PMID: 39802765 Free PMC article. Preprint.
4,710 results